Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.7M | $22.8M | $17.0M | $29.3M | $42.2M | $80.9M | $154M | $258M | $426M | $510M |
| Revenue growth | — | 113.5% | -25.4% | 72.8% | 43.9% | 91.7% | 90.4% | 67.6% | 65.2% | 19.6% |
| Gross profit | $4.30M | -$6.40M | -$25.2M | — | -$19.1M | $1.17M | $35.3M | $88.9M | $220M | $293M |
| Gross margin | 40.3% | -28.1% | -148.4% | — | -45.2% | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% |
| Operating income | -$17.3M | -$39.3M | -$60.3M | -$41.4M | -$64.9M | -$58.4M | -$39.4M | $21.6M | $139M | $191M |
| Operating margin | -162.6% | -172.7% | -354.9% | -141.1% | -153.8% | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% |
| Net income | -$19.5M | -$43.8M | -$65.7M | -$48.3M | -$75.7M | -$71.6M | -$65.9M | -$28.2M | $198M | $147M |
| Net margin | -183.1% | -192.3% | -387.1% | -164.5% | -179.4% | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% |
| EPS (diluted) | -$1.61 | -$1.91 | -$1.45 | -$0.89 | -$0.88 | -$0.51 | -$0.33 | -$0.13 | $0.81 | $0.60 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.3M | -$37.3M | -$62.7M | -$76.2M | -$102M | -$112M | -$59.5M | $8.80M | $119M | $50.4M |
| Capital expenditures | $73.4K | $2.68M | $2.10M | $3.81M | $12.7M | $13.5M | $13.9M | $4.77M | $8.23M | $22.6M |
| Free cash flow | -$18.3M | -$39.9M | -$64.8M | -$80.0M | -$115M | -$126M | -$73.4M | $4.03M | $110M | $27.8M |
| Share buybacks | — | — | — | — | — | — | — | $0.00 | $0.00 | $31.9M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9.91M | $43.1M | $26.8M | $26.8M | $55.9M | $51.1M | $86.5M | $51.4M | $103M | $87.6M |
| Total assets | $23.7M | $108M | $88.9M | $127M | $208M | $276M | $348M | $329M | $489M | $624M |
| Total liabilities | $28.1M | $67.7M | $69.1M | $101M | $119M | $135M | $196M | $194M | $140M | $147M |
| Long-term debt | $1.79M | $2.76M | $2.76M | $0.00 | — | — | — | — | $72.3M | $69.3M |
| Shareholders' equity | -$4.46M | $40.3M | $19.8M | $26.2M | $88.2M | $141M | $152M | $135M | $349M | $477M |
| Retained earnings | -$107M | -$151M | -$216M | -$265M | -$340M | -$412M | -$478M | -$506M | -$309M | -$162M |
| Shares (wtd avg diluted) | 12.9M | 36.7M | 46.4M | 59.3M | 86.1M | 140M | 198M | 224M | 243M | 245M |
Every figure is extracted from ADMA BIOLOGICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.